Exagen Diagnostics | GenomeWeb

Exagen Diagnostics

NEW YORK (GenomeWeb) – Exagen Diagnostics said in a regulatory document that its revenues through the first nine months of 2014 grew almost four-fold year over year.

Biogen Idec has hired Olivier Danos as senior VP of gene therapy. Danos will report to Douglas Williams, executive VP of R&D at Biogen Idec. At Biogen Idec, he will be in charge of the gene therapy research group, which develops new technologies for gene transfer and genome engineering.

Exagen Raises $3.95M

NEW YORK (GenomeWeb) – Rheumatology and autoimmune diagnostics firm Exagen Diagnostics has raised $3.95 million, it said in a regulatory document on Monday.

Exagen Diagnostics, a rheumatology-focused diagnostics company, announced that Arthur Weinstein will become its newest board member and advise the company's scientific team.

NEW YORK (GenomeWeb News) – Exagen Diagnostics this week said in a regulatory filing that it raised a little more than $5 million in an equity financing round.

NEW YORK (GenomeWeb News) – Exagen Diagnostics today said that New York has approved its Avise SLE diagnostic, SLE-Systemic Lupus Erythematosus.

NEW YORK (GenomeWeb News) – Exagen Diagnostics, which develops genomic tests aimed at rheumatology, announced on Monday the completion of a financing round that raised $5.3 million.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Exagen will pay Cypress up to $8 million in upfront and milestone payments as well as additional royalty payments for the business.

The molecular diagnostics firm becomes one of more than 17,000 labs around the world to receive such accreditation.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.